Article
26 Nov 2025
FDA Approves Accord BioPharma's Denosumab Biosimilars
AUTHORS CONTENT
Article
26 Nov 2025
Sandoz Launches Natalizumab Biosimilar
Article
05 Nov 2025
FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars
Article
16 Oct 2025
Amgen And Biocon Settle Denosumab BPCIA Case
Article
06 Jun 2025
Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector In Europe
Article
02 Sep 2024
Del. Judge Connolly Says Preambles Are Limiting, Cites Alice In Wonderland, And Invites The Federal Circuit To Weigh In
Article
16 Aug 2024
Genzyme Sues Sarepta For Infringement Of Gene Therapy Patents
Article
05 Mar 2024
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)
Article
17 Oct 2023
Update On Ophthalmic Anti-VEGF Therapeutics
Article
03 Aug 2023
Update: Post-Trial Briefing In Regeneron v. Mylan Aflibercept BPCIA Case Now Complete
Article
03 Jul 2023
FDA Accepts Xbrane's SBLA For LUCENTIS® (Ranibizumab) Biosimilar Candidate
Article
25 May 2023
Amneal Launches FYLNETRA (pegfilgrastim-pbbk) In The United States
Article
27 Apr 2023
Mabwell Announces Approval Of Denosumab Biosimilar MAILISHU In China
Article
17 Feb 2023
FDA Approves EYLEA® (Aflibercept) For Treatment Of Retinopathy Of Prematurity
Article
16 Feb 2023
Biosimilar Clinical Trial Updates
Article
02 Feb 2023
Amgen Launches AMJEVITA—First Biosimilar To HUMIRA In The United States
Article
15 Nov 2022
PTAB Issues Final Written Decisions Finding Claims Of Regeneron's Aflibercept Patents Invalid